Skip to main content
. 2021 Dec 2;75(4):690–701. doi: 10.1093/cid/ciab988

Figure 4.

Figure 4.

Secondary endpoints: confirmed viremia clearance and symptom control at week 8 and maintained through week 12, week 16 (key secondary endpoint), and week 20 (randomized population). Symptom control was defined as resolution/improvement of CMV disease/syndrome for patients symptomatic at baseline or absence of the development of CMV disease/syndrome for patients asymptomatic at baseline. Abbreviations: CI, confidence interval; CMV, cytomegalovirus; IAT, investigator-assigned therapy.